By inhibiting the release of pro-inflammatory cytokines, such as TNF-α and IL-6, it emerges as a promising therapeutic agent for chronic inflammatory disorders, including rheumatoid arthritis and inflammatory bowel disease [87]. Here, IL6 is linked to inflammatory bowel disease.